These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36465803)

  • 21. Comparing the efficacy and safety of low, medium, and high dosages of selexipag for treating pulmonary hypertension: A systematic review and meta-analysis.
    Wang S; Yan Y; Zhang J; Yuan P; Luo CJ; Qiu HL; Li HT; Xu J; Wang L; Li TL; Jiang R
    Animal Model Exp Med; 2024 Feb; 7(1):56-70. PubMed ID: 37740617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.
    Song C; Kunovszki P; Beaudet A
    J Health Econ Outcomes Res; 2022; 9(1):151-160. PubMed ID: 35800882
    [No Abstract]   [Full Text] [Related]  

  • 23. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single-centre experience.
    Vlachou M; Fayed H; Dawson A; Reddecliffe S; Stevenson A; Thomson RJ; Schreiber BE; Coghlan JG
    Rheumatology (Oxford); 2022 Mar; 61(3):1106-1114. PubMed ID: 34142120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).
    Tamura Y; Kumamaru H; Tsujino I; Suda R; Abe K; Inami T; Horimoto K; Adachi S; Yasuda S; Sera F; Taniguchi Y; Kuwana M; Tatsumi K;
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients.
    Aldweib N; Verlinden NJ; Kassis-George H; Raina A
    Pulm Circ; 2021; 11(4):20458940211036623. PubMed ID: 34646497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension.
    Rothman A; Cruz G; Evans WN; Restrepo H
    Pulm Circ; 2020; 10(1):2045894019876545. PubMed ID: 32110381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selexipag for the treatment of pulmonary arterial hypertension.
    Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
    Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of oral therapies targeting the prostacyclin pathway in pulmonary arterial hypertension: A systematic review and network meta-analysis.
    Manzi G; Mariani MV; Filomena D; Papa S; Recchioni T; Scoccia G; Vizza CD; Badagliacca R
    Int J Cardiol; 2023 Dec; ():131691. PubMed ID: 38158135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Right ventricular afterload predicts long-term transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Maestas T; Hansen LM; Vanderpool RR; Desai AA; Airhart S; Knapp SM; Cohen A; Feldman J; Rischard FP
    Pulm Circ; 2018; 8(4):2045894018797270. PubMed ID: 30124133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.
    Colglazier E; Ng AJ; Parker C; Nawaytou H; Fineman JR
    J Pediatr Pharmacol Ther; 2021; 26(5):512-516. PubMed ID: 34239406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids.
    Bartolome SD; Sood N; Shah TG; Styrvoky K; Torres F; Chin KM
    Chest; 2018 Sep; 154(3):532-540. PubMed ID: 29679599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.
    Blissett S; Blusztein D; Mahadevan VS
    Eur Heart J Case Rep; 2020 Dec; 4(6):1-7. PubMed ID: 33442633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension.
    Verlinden NJ; Benza RL; Raina A
    Pulm Circ; 2020; 10(4):2045894020945523. PubMed ID: 33354314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
    Ataya A; Somoracki A; Cope J; Alnuaimat H
    Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
    Safdar Z
    Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.